📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. (2016)

First Author: Wilson JM

Attributed to: Molecular determinants of Radiosensitivity funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.radonc.2016.03.021

PubMed Identifier: 27117177

Publication URI: http://europepmc.org/abstract/MED/27117177

Type: Journal Article/Review

Volume: 119

Parent Publication: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Issue: 2

ISSN: 0167-8140